Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Research & Development for 8 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 44.09% year-over-year to $24.5 million, compared with a TTM value of $112.2 million through Dec 2025, down 42.5%, and an annual FY2025 reading of $112.2 million, down 42.5% over the prior year.
  • Research & Development was $24.5 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $23.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $58.7 million in Q2 2024 and bottomed at $23.3 million in Q3 2025.
  • Average Research & Development over 5 years is $41.1 million, with a median of $41.5 million recorded in 2024.
  • The sharpest move saw Research & Development surged 532.18% in 2021, then tumbled 49.58% in 2025.
  • Year by year, Research & Development stood at $32.6 million in 2021, then decreased by 17.32% to $27.0 million in 2022, then soared by 35.73% to $36.6 million in 2023, then grew by 19.55% to $43.8 million in 2024, then plummeted by 44.09% to $24.5 million in 2025.
  • Business Quant data shows Research & Development for ARCT at $24.5 million in Q4 2025, $23.3 million in Q3 2025, and $29.6 million in Q2 2025.